--- a
+++ b/clusters/9knumclustersv2/clust_1372.txt
@@ -0,0 +1,18 @@
+Treatment with systemic immunostimulatory agents within  weeks or  half-lives of the drug, whichever is longer, prior to initiation of study treatment
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug (whichever is longer) prior to randomization
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment
+Treatment with systemic immunostimulatory agents;
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment (with the exception of checkpoint blockade therapy)
+Patients who receive treatment with systemic immunostimulatory agents (including but not limited to IFNs, IL-) within  weeks or five half-lives of the drug, whichever is shorter, prior to study registration are not eligible
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to initiation of study treatment
+Treatment with systemic immunostimulatory agents within  weeks or  half-lives of the drug, whichever is longer, prior to Cycle , Day 
+Treatment with systemic immunostimulatory agents (including but not limited to interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to first dose.
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to first dosing.
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug (whichever is shorter) prior to randomization
+Receiving systemic immunostimulatory agents within  weeks or  half-lives, whichever is shorter, prior to first dose of study treatment (except ant PD-/PD-L treatment if recruited into Group a or b).
+Treatment with systemic immunostimulatory agents within  weeks or  half-lives of the drug (whichever is longer) prior to enrollment
+Treatment with systemic immunostimulatory agents
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to the first dose of study treatment
+Treatment with immunostimulatory agents within  weeks or immunosuppressive agents within  weeks prior to randomization
+Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is longer, prior to screening
+Treatment with systemic immunostimulatory agents